Highest-materiality recent filing
LeMaitre Vascular 2026 annual meeting results; director John Roush gets 29% withheld votes
Two Class II directors elected: David B. Roberts (18.9M for, 1.25M withheld) and John A. Roush (14.2M for, 5.9M withheld).
LeMaitre Q1 2026 sales $66.6M (+11%), EPS $0.68 (+42%); raises FY guidance
Q1 sales $66.6M (up 11% YoY, 10% organic); gross margin 72.7% (+350 bps); EPS $0.68 (+42%).
LeMaitre Vascular director Bridget Ross not standing for re-election; board rebalanced
Bridget Ross will not stand for re-election as Class II director at June 2, 2026 Annual Meeting, serving until term ends; no disagreement with company.
LeMaitre Q4 2025 sales $64.5M (+16%), EPS $0.68 (+39%), raises dividend 25%
Q4 2025 sales $64.5M (+16% YoY, +15% organic); diluted EPS $0.68 (+39%).
LeMaitre Vascular Board adopts annual say-on-pay votes after stockholder preference
Stockholders voted at June 2, 2025 annual meeting for annual say-on-pay frequency.
LeMaitre Q3 sales $61.0M (+11%), EPS $0.75 (+54%); raises FY guidance
Q3 sales $61.0M (+11% YoY, +12% organic); Grafts +23%, Shunts +18%, Artegraft +33%.
LeMaitre Vascular Q2 sales up 15% to $64.2M; raises FY guidance
Q2 EPS $0.60 (+16% YoY); sales $64.2M (+15% organic) driven by catheters (+27%) and grafts (+19%).
LeMaitre Vascular holds 2025 annual meeting; all four proposals approved by stockholders
Elected three Class I directors: LeMaitre (18.4M for, 1.6M withheld), Roberts (18.2M for, 1.8M withheld), Shadan (15.2M for, 4.8M withheld).
LeMaitre Vascular Q1 sales $59.9M (+12% YoY), raises FY guidance, declares $0.20 dividend
Q1 sales $59.9M, +12% reported (+13% organic); EPS $0.48, +10% YoY.
LeMaitre Q4 sales $55.7M (+14%), EPS $0.49 (+30%), raises dividend 25%
Q4 sales $55.7M (+14% organic), EPS $0.49 (+30%), op income $12.9M (+26%).
LeMaitre Vascular appoints Dorian LeBlanc as CFO; base salary $565,000, target bonus $225,000
Dorian LeBlanc appointed CFO effective March 10, 2025; previously CFO at LumiraDx (acquired by Roche).
LeMaitre Vascular issues $172.5M of 2.50% convertible notes due 2030
Issued $150M principal amount plus $22.5M from initial purchasers' option exercise.
LeMaitre Vascular prices $150M convertible senior notes offering
$150M aggregate principal of 2.50% Convertible Senior Notes due 2030, interest payable semi-annually.
LeMaitre Vascular announces $150M convertible senior notes offering due 2030
Offering of $150M aggregate principal amount of Convertible Senior Notes due 2030.
LeMaitre Vascular Q3 sales up 16% to $54.8M, EPS $0.49 (+46%), raises full-year guidance
Q3 sales $54.8M (+16% organic); diluted EPS $0.49, +46% YoY.
CFO Joseph P. Pellegrino Jr. to retire effective March 7, 2025; remains on Board
Pellegrino will retire as employee and CFO on March 7, 2025, after 2024 10-K filing; stays on Board until June 2027.
LeMaitre Q2 EPS $0.52 +44%, FY guidance raised; dividend $0.16
Sales $55.8M +11% (+12% organic); EPS $0.52 +44% vs Q2 2023.
Director Jasinski fails to win majority vote at annual meeting; board rejects resignation
Lawrence J. Jasinski received 8.28M for vs 11.31M withheld, triggering resignation policy; board rejected resignation on June 3.
LeMaitre Vascular Q1 sales $53.5M (+14%), EPS $0.44 (+62%); raises FY op. margin guidance to 22%
Q1 net income $9.9M (+64%); gross margin 68.6% (+300 bps) on price increases and manufacturing efficiencies.
LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback
Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).
LeMaitre Q3 sales $47.4M (+21%); EPS $0.33; declares $0.14 dividend; guides Q4 $48-50M
Q3 sales $47.4M (+21% YoY, +16% organic); net income $7.5M (+38%); diluted EPS $0.33 (+36%).
LeMaitre Q2 sales up 19% to $50.1M; EPS $0.36 (+127%); FY23 guidance raised; $0.14 dividend
Sales $50.1M, +19% (+16% organic) vs Q2 2022; operating income $9.5M (+63%).
LeMaitre Vascular announces 2023 annual meeting voting results
Bridget A. Ross elected as Class II director with 14,649,999.71 votes for, 4,496,976 withheld.
LeMaitre Q1 sales up 22% organic to $47.1M; EPS flat at $0.27; issues guidance
Sales $47.1M, +19% (+22% organic); net income $6.0M flat; diluted EPS $0.27 (-1%).
Q4 sales $41.0M (+4% reported, +8% organic); net income $5.6M (-9%); EPS $0.25 (-9%).
LeMaitre Q3 sales $39M (+2%), EPS $0.25 (-17%); declares $0.125 dividend
Q3 sales $39.0M (+2% reported, +7% organic YoY); EPS $0.25 diluted, down 17%.
LeMaitre Vascular appoints Martha Shadan to Board of Directors
Board expanded to eight seats; Martha Shadan appointed as Class I director effective Sept 21, 2022.
LeMaitre Vascular Q2 sales $42.1M (+8% organic); raises FY guidance to 10% organic growth
Q2 2022 sales $42.1M (+4%, +8% organic); reported EPS $0.16 (-60%); adjusted EPS ex-special charge $0.29 (-26%).
George W. LeMaitre elected with 16,025,727.6 votes for; David B. Roberts with 17,820,028.6 votes for; both serve three-year terms until 2025.
LeMaitre Q1 sales $39.6M (+13% organic), EPS $0.27; guides FY $160-164M, closes French factory
Q1 sales $39.6M, +10% YoY (+13% organic); net income $6.0M, +2%; EPS $0.27, -4%.
LeMaitre Q4 2021 revenue $39.5M (+5%), EPS $0.28 (-18%); raises dividend 14%
Q4 2021 sales $39.5M (+5% YoY); net income $6.2M (-12%); diluted EPS $0.28 (-18%).
LeMaitre Vascular terminates $65M credit facility; records $0.5M non-cash charge
Terminated Credit Agreement with KeyBank and Truist; no borrowings outstanding at termination.
LeMaitre Q3 sales $38.4M (+5% organic), EPS $0.30 (-19%), declares $0.11 dividend
Net income $6.5M (-13%), op. income $9.1M (-9%), gross margin 64.8% (+250 bps).
On August 28, 2021, LeMaitre amended its 2019 asset purchase agreement with Anteris Technologies (formerly Admedus).
LeMaitre Vascular secures full exercise of underwriters' option for 150k shares at $54.50
Underwriters fully exercised option to purchase 150,000 additional common shares on August 4, 2021.
LeMaitre Q2 2021 sales $40.7M (+64% YoY), EPS $0.40; declares $0.11 dividend; FY21 guidance raised
Sales $40.7M (+64% or +35% organic); operating income $11.1M (+128%); net income $8.3M (+137%); diluted EPS $0.40 (+131%).
LeMaitre Vascular closes public offering of 1M shares at $54.50, netting ~$51M
Sold 1,000,000 shares at $54.50 per share; underwriters have 30-day option for up to 150,000 additional shares.
LeMaitre Q2 net sales $40.7M (+64%), op income up ~128%; launches stock offering, receives CE marks
Q2 preliminary net sales $40.7M (+64% reported, +35% organic vs Q2 2020).
LeMaitre Vascular increases CEO annual equity to $1.1M, raises executive salaries for 2022
CEO annual equity value increased from $725k to $1.1M; other NEOs: Pellegrino $250k->$500k, Roberts $250k->$500k, Kamke $115k->$225k.
On February 7, 2025, LeMaitre Vascular, Inc. (the “Company”) agreed to terms with Dorian LeBlanc to become the Chief Financial Officer and principal financial officer of the Company, effective on March 10, 2025.
On August 26, 2024, LeMaitre Vascular, Inc. (the “Company”), announced that Joseph P. Pellegrino, Jr. will retire as an employee of the company, including as Chief Financial Officer, effective as of March 7, 2025, following the anticipated filing of the 2024 Fiscal Year 10-K.
the Board appointed Martha Shadan as a director of the Company effective as of such date
Max materiality 0.85 · Median 0.70 · Most common event earnings